NCT05997056 - Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

May 9, 2025

Study Completion Date

December 8, 2025

Conditions

Neuroendocrine TumorsNETPancreatic Neuroendocrine TumorGastrointestinal Neuroendocrine TumorPulmonary Neuroendocrine Tumor

Interventions

DRUG

nab-sirolimus

Prospective phase 2 single arm, open-label, multi-institutional study to determine the efficacy and safety prospective of nab-sirolimus administered by IV infusion

Trial Locations (4)

53226

RECRUITING

Medical College of Wisconsin Cancer Center, Milwaukee

75246

RECRUITING

Texas Oncology, Dallas

80218

RECRUITING

Rocky Mountain Cancer Centers, Denver

92663

RECRUITING

Hoag Memorial Hospital Presbyterian, Newport Beach